What does Stately Bio do?
Stately Bio is a biotechnology company that leverages machine learning and live-cell imaging technology to provide rapid, real-time insights into cell identity, quality, and behavior, supporting advancements in regenerative medicine.
How much did they raise?
The company secured $12M in Seed funding, led by AIX Ventures, with additional investments from Dimension Capital, Foothill Ventures, Village Global, Caffeinated Capital, Mitsui Global Investment, BoxOne Ventures, Axial VC, Jeff Dean, Jeremy Wertheimer, and Tom Berry.
What are their plans for the money?
With the new funds, Stately Bio plans to scale its platform technology, expand its suite of stem cell-derived therapeutics, and explore new partnerships to further utilize its industry-leading liver cell program for toxicity testing, disease modeling, and therapeutic applications.
What have they achieved so far?
The company has already made significant strides by demonstrating a 3x-10x improvement in key metabolic assays for liver cell functionality compared to current state-of-the-art methods.
